Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) shares saw strong trading volume on Monday . Approximately 1,508,580 shares were traded during trading, an increase of 394% from the previous session’s volume of 305,110 shares.The stock last traded at $14.9450 and had previously closed at $14.19.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on CTNM shares. Morgan Stanley boosted their target price on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered Contineum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Royal Bank Of Canada lifted their price objective on Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.25.
Check Out Our Latest Stock Report on CTNM
Contineum Therapeutics Price Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05. On average, equities research analysts predict that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Contineum Therapeutics
Institutional investors have recently modified their holdings of the company. Strs Ohio bought a new stake in Contineum Therapeutics in the 1st quarter valued at about $27,000. China Universal Asset Management Co. Ltd. acquired a new position in Contineum Therapeutics during the 4th quarter valued at about $43,000. Qube Research & Technologies Ltd bought a new position in Contineum Therapeutics in the 2nd quarter worth about $43,000. Marex Group plc bought a new position in Contineum Therapeutics in the 2nd quarter worth about $45,000. Finally, Royal Bank of Canada increased its stake in shares of Contineum Therapeutics by 73.5% in the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after purchasing an additional 2,454 shares during the period.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Featured Articles
- Five stocks we like better than Contineum Therapeutics
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
